ArticleACG case reports journal2025
Successful Endoscopic Ultrasound-Guided Radiofrequency Ablation for Symptomatic Insulinoma in a High-Risk Elderly Patient.
Article in ACG case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA): Are We Getting Evidence-Based Results? A Systematic Review According to the Levels of Evidence.Medicina (Kaunas, Lithuania) · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe a case of symptomatic pancreatic insulinoma in an 80-year-old man with multiple comorbidities. The patient underwent endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA). After biochemical suspicion of endogenous hyperinsulinemic hypoglycemia, imaging revealed a 9 × 18 mm pancreatic body mass confirmed as a World Health Organization grade 1 insulinoma on histopathology. Given the high surgical risk, we performed a EUS-RFA with 13 sequential ablations. Blood glucose normalized within 48 hours postprocedure. The lesion reduced significantly in size, with no recurrence of hypoglycemia observed up to an 18-month follow-up. EUS-RFA offers a safe and effective alternative to surgery for insulinoma in medically vulnerable patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.